“Promising PCR Rate in Early-Stage TNBC with Neoadjuvant Camrelizumab Plus Non-Platinum-Based Chemotherapy in Experimental Trial” or “TAP1 and IRF4 as Potential Predictive Biomarkers for Response to Neoadjuvant NAT in Early-Stage TNBC: Experimental Single-Arm Phase II Clinical Trial Results”

https://pubmed.ncbi.nlm.nih.gov/38116673

The experimental single-arm phase II clinical trial shows that neoadjuvant camrelizumab plus non-platinum-based chemotherapy has a promising pCR rate in early-stage TNBC, with an acceptable safety profile, and TAP1 and IRF4 may serve as potential predictive biomarkers for response to the NAT.